Human monoclonal antibodies specific for FLT3 and uses thereof

US11236171B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Dimiter S. Dimitrov · Frederick, US
• Weizao Chen · Frederick, US
• Terry J. Fry · Denver, US
• Christopher D. Chien · Falls Church, US
• Haiying Qin · Potomac, US

Key dates

• Filing date: Dec 21, 2017
• Grant date: Feb 1, 2022
• Expiry date: Mar 16, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.